Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06898957 | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) | PHASE1 | ACTIVE NOT_RECRUITING | 29 | — | — | May 16, 2025 | Jun 23, 2031 | May 20, 2026 | 36 | United States, Canada +8 |
| Arm | Type | Description |
|---|---|---|
| Dose Exploration (Part 1) | EXPERIMENTAL | Multiple dose levels of YL201 will be explored in combination with tarlatamab administered intravenously (IV) at a fixed dose using one-step dosing. |
| Dose Expansion (Part 2) | EXPERIMENTAL | YL201 will be administered at the selected maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) in combination with tarlatamab administered IV at a fixed dose. |
| Triplet Combination (Part 3) | EXPERIMENTAL | YL201 will be administered at MTCD or RP2D in combination with tarlatamab and an anti-PD-L1 (durvalumab) administered IV at a fixed dose. |
| Name | Type | Description |
|---|---|---|
| YL201 | DRUG | YL201 will be administered as an IV infusion. |
| Tarlatamab | DRUG | Tarlatamab will be administered as an IV infusion. |
| Durvalumab | DRUG | Durvalumab will be administered as an IV infusion. |
Inclusion Criteria: * Participants ≥ 18 years of age (or legal adult age within country) at time of signing informed consent. * Participants with histologically or cytologically confirmed ES-SCLC. * For Parts 1 and 2, subjects must have ES-SCLC that has progressed or recurred following at least 1 p...